IPP Bureau
Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
By IPP Bureau - January 23, 2025
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
By IPP Bureau - January 23, 2025
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Budget 2025: Industry expects tax incentives and thrust on affordable healthcare
By IPP Bureau - January 23, 2025
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Glenmark Pharmaceuticals USA launches Phytonadione Injectable Emulsion USP
By IPP Bureau - January 22, 2025
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Kwality Pharmaceuticals receives SFDA GMP approval for 2 units
By IPP Bureau - January 22, 2025
This certification will open new markets for the Kwality Pharma
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US
By IPP Bureau - January 22, 2025
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Sunshine Biopharma launches Olanzapine and Olanzapine ODT
By IPP Bureau - January 22, 2025
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets
By IPP Bureau - January 21, 2025
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer
By IPP Bureau - January 21, 2025
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Moderna announces updates on pandemic influenza program
By IPP Bureau - January 21, 2025
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
.jpg "Briefs: Cipla and IOL Chemicals and Pharmaceuticals")
Briefs: Cipla and IOL Chemicals and Pharmaceuticals
By IPP Bureau - January 21, 2025
Mesalazine is used to treat inflammatory bowel disease
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
By IPP Bureau - January 19, 2025
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Glenmark Life Sciences rebranded as Alivus Life Sciences
By IPP Bureau - January 19, 2025
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
GCPB revokes closure order of Aarti Pharmalabs’s Vapi plant
By IPP Bureau - January 19, 2025
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Heraeus acquires Umicore’s Platinum API business outside of South America
By IPP Bureau - January 19, 2025
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
